<DOC>
	<DOCNO>NCT02954991</DOCNO>
	<brief_summary>The study evaluate clinical activity nivolumab combination 3 separate investigational agent , glesatinib , sitravatinib , mocetinostat .</brief_summary>
	<brief_title>Phase 2 Study Glesatinib , Sitravatinib Mocetinostat Combination With Nivolumab Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Glesatinib orally administer multi-targeted tyrosine kinase inhibitor ( TKI ) primarily target Axl Mesenchymal-Epithelial Transition ( MET ) receptor . Sitravatinib orally-available , potent small molecule inhibitor closely related spectrum receptor tyrosine kinase ( RTKs ) include MET , Axl , MERTK , VEGFR family , PDGFR family , KIT , FLT3 , Trk family , RET , DDR2 select Eph family member . Mocetinostat orally administer histone deacetylase ( HDAC ) inhibitor . Nivolumab human IgG monoclonal antibody bind program cell death-1 ( PD-1 ) receptor block interaction program cell death ligand-1 ( PD-L1 ) PD-L2 , release PD-1 pathway-mediated inhibition immune response include anti-tumor immune response . Combining immunotherapeutic PD-L1 checkpoint inhibitor agent immune modulatory antitumor property could enhance antitumor efficacy observe either agent alone . The study lead-in dose escalation evaluation two dose level investigational agent combination nivolumab . Following completion lead-in dose escalation , enrollment Phase 2 study proceed .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Diagnosis nonsmall cell lung cancer . Prior treatment platinum base doublet checkpoint inhibitor Adequate bone marrow organ function Uncontrolled tumor brain Unacceptable toxicity prior checkpoint inhibitor Impaired heart function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>